American chemical industry news (page 20)

• 

  28 October 2025

  Novo Nordisk to Present Wegovy® Data at 2025 AASLD Meeting

  11 abstracts on Wegovy® and MASH to be presented at AASLD 2025, highlighting clinical and real-world data, including post-hoc analyses of the ESSENCE trial.
• 

  28 October 2025

  Merck's KEYTRUDA and WELIREG Combo Improves DFS in RCC Patients Post-Nephrectomy

  The LITESPARK-022 trial shows improved DFS with KEYTRUDA and WELIREG in RCC patients. Safety profiles align with previous studies. Results to be shared with regulators.
• 

  28 October 2025

  Merck and Eisai's WELIREG and LENVIMA Improve PFS in Advanced Renal Cell Carcinoma Trial

  The trial showed significant PFS and ORR improvements with WELIREG and LENVIMA in advanced RCC patients post anti-PD-1/L1 therapy, with consistent safety profiles.
• 

  28 October 2025

  Roche's Gazyva Shows Positive Phase III Results in Pediatric Nephrotic Syndrome

  Gazyva achieved sustained remission in young nephrotic syndrome patients, reducing steroid use. No new safety issues. Data to be shared with health authorities.
• 

  27 October 2025

  Dow's Freeport MDI Facility Achieves ISCC PLUS Certification

  The Freeport facility now offers bio-circular isocyanates with ISCC PLUS certification, enhancing sustainability and supply chain transparency for various industries.
• 

  27 October 2025

  Iberdrola Wins M&A Value Award

  Iberdrola's strategic M&A activities, including 26 deals worth over €18.5B, have accelerated its growth, meeting 2026 targets early and boosting its market position.

• 

  27 October 2025

  Merck's WINREVAIR Approved by FDA for Expanded PAH Treatment

  WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.
• 

  27 October 2025

  Johnson & Johnson's Icotrokinra Shows Therapeutic Benefit and Safety in Ulcerative Colitis

  Icotrokinra shows sustained clinical benefits and safety in ulcerative colitis, with Phase 3 trials underway for broader applications.
• 

  27 October 2025

  Johnson & Johnson Study Highlights Unmet Psoriasis Needs and Preference for Effective Oral Treatments

  The ENCOMPASS study shows significant psoriasis burden and preference for oral treatments, highlighting unmet needs in patient care and quality of life impacts.
• 

  27 October 2025

  Johnson & Johnson's TREMFYA® Shows Two-Year Remission in Crohn's Disease

  TREMFYA® maintains remission in Crohn's disease over 96 weeks, with consistent safety and efficacy in both subcutaneous and intravenous regimens.
• 

  24 October 2025

  Johnson & Johnson: Nipocalimab Reduces Sjögren’s Disease Activity and Severity

  Nipocalimab shows promise in reducing Sjögren’s disease symptoms and autoantibodies, with a favorable safety profile and ongoing Phase 3 trials.
• 

  24 October 2025

  Merus Reports Positive Interim Data on Petosemtamab in Metastatic Colorectal Cancer

  Petosemtamab shows promising response rates in 1L and 2L mCRC, with potential as a new standard of care.
• 

  24 October 2025

  Kemira Oyj Q3 2025: Profitability Steady Amid Market Challenges

  Revenue and EBITDA declined due to market softness. Water Solutions remained strong. Strategic acquisitions and partnerships aim to boost growth. 2025 outlook remains unchanged.
• 

  24 October 2025

  Kemira Acquires Water Engineering, Inc.

  The acquisition enhances Kemira's North American market position and water treatment capabilities, integrating Water Engineering, Inc. into its Water Solutions unit.
• 

  23 October 2025

  Iberdrola's Ignacio Galán Wins 2025 International Energy Award in Qatar

  Galán honored for advancing renewables, transforming Iberdrola into a global leader. Iberdrola plans €58B investment in grids by 2028, focusing on the UK and US.
• 

  23 October 2025

  Neste and United Airlines Expand SAF Supply to Three Major US Airports

  United Airlines will use Neste's SAF at Houston, Newark, and Dulles airports, aiming to reduce emissions and promote sustainable aviation with government support.
• 

  23 October 2025

  Dow Q3 2025 Financial Results

  Net sales down 8% YoY. Volume stable. GAAP net income $124M. Cash flow improved. Cost reductions ongoing. Packaging & Specialty Plastics and Industrial Intermediates face pricing pressures.
• 

  23 October 2025

  Merck's KEYTRUDA and KEYTRUDA QLEX Get FDA Priority Review for Bladder Cancer Treatment

  FDA grants priority review for KEYTRUDA combinations with Padcev, showing improved survival in muscle-invasive bladder cancer patients ineligible for cisplatin-based chemotherapy.
• 

  23 October 2025

  Elkem Q3 2025: Strong Operations and Cost Improvements Boost Results

  EBITDA fell 33% YoY due to low sales prices. Silicones division under review for sale. EU and US trade measures may impact future performance.
• 

  23 October 2025

  INEOS Alerts Europe on Risk to Medicine Supply

  European BDO production is threatened by cheap imports from China, risking jobs and medicine supply chains. Urgent EU action is needed to block unfair competition and protect local industry.
• 

  22 October 2025

  Boehringer Ingelheim's JASCAYD® Approved in China for IPF Treatment

  Nerandomilast, approved in China for IPF, showed significant lung function improvement in Phase III trials. It offers favorable tolerability and is also FDA-approved in the U.S.
• 

  22 October 2025

  Symrise Invests in Cellibre to Boost Innovation in Taste and Cosmetic Markets

  Symrise gains access to Cellibre's fermentation tech for scalable, sustainable ingredient production, enhancing supply chain resilience and aligning with sustainability goals.
• 

  22 October 2025

  EnviTec Biogas AG Wins 2025 Energy Vision Leadership Award

  EnviTec recognized for advancing clean energy and circular economy, with notable projects like Germany's largest bio-LNG plant, Güstrow, highlighting economic and environmental benefits.
• 

  22 October 2025

  WuXi Biologics Joins Hang Seng Corporate Sustainability Index

  Recognized for ESG excellence, the company advances sustainable practices and aligns with global initiatives, earning multiple sustainability accolades and maintaining a strong industry presence.
• 

  21 October 2025

  Takeda Partners with Innovent on Oncology Medicines

  Takeda gains rights to two late-stage cancer drugs and an option for an early-stage program, focusing on global development and commercialization outside Greater China.
• 

  21 October 2025

  BASF and IFF Collaborate on Enzyme and Polymer Innovation

  The collaboration aims to develop sustainable enzyme and polymer technologies for cleaning and personal care, enhancing performance and reducing environmental impact.
• 

  21 October 2025

  Port of Antwerp-Bruges: Mixed Results Amid Volatile Market

  Container traffic stabilizes, bulk declines due to global uncertainty. US tariffs impact exports. European chemical sector faces challenges. RoRo and US trade show growth.
• 

  20 October 2025

  Perpetual Next Appoints Gervais Green to Supervisory Board, Continues Partnership with ING Corporate Finance

  Gervais Green joins to enhance governance and international growth. Collaboration with Fluor and ING supports biomethanol expansion and strategic partner admission.
• 

  20 October 2025

  Merck Begins $3B Pharmaceutical Facility Construction in Virginia

  Merck invests $70B in U.S. manufacturing and R&D, creating 500+ full-time and 8,000 construction jobs in Virginia, enhancing biopharmaceutical innovation and domestic production.
• 

  20 October 2025

  Novo Nordisk to Present Oral Semaglutide and Obesity Data at ObesityWeek 2025

  New data on oral semaglutide and CagriSema will be presented, focusing on weight loss efficacy, cardiometabolic health, and women's health in obesity management.